SRA 737Alternative Names: CCT 245737; PNT737; SRA737
Latest Information Update: 11 Jan 2017
At a glance
- Originator Cancer Research Technology; Sareum; The Institute of Cancer Research
- Developer The Institute of Cancer Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours